| 1 | Abnova December E-Newsletter - Product News : Abnova launched 800 full-length proteins, 84 Mab, and 490 MaxPab® antibodies. Find your target and try it today! http://www.abnova.com/products/new_products.asp . 800 New Full-length Proteins , 84 New Monoclonal Antibodies , 490 New MaxPab® Antibodies , 490 Western Blot (Transfected lysate) , 52 Immunohistochemistry & 193 Sandwich ELISA .. Read more |
| 2 | Abnova November E-Newsletter - Product News: Latest News on Cancer Research. 1179 New Full-length Proteins / 125 New Partial-length Proteins , 196 New Monoclonal Antibodies / 269 New Polyclonal Antibodies Go to the total monoclonal antibody list, 55 New RNAi Knockdown (Antibody Validated) ,105 Western Blot (Cell lysate),131 RNAi Knockdown (Antibody validated) ,20 Western Blot (Tissue lysate),51 Immunohistochemistry,129 Western Blot (Transfected lysate) ,257 Immunofluorescence,4084 Sandwich ELISA,49 Immunoprecipitation ... |
| 3 | Abnova October E-Newsletter - Story and Product Focus , EIF2C2 mmunoperoxidase of monoclonal antibody to EIF2C2 (Cat # H00027161-M01 ) on formalin-fixed paraffin-embedded human stomach. [antibody concentration 3ug/ml] EIF2C2 encodes a member of the Argonaute family of proteins which play a role in RNA interference. The encoded protein is highly basic, and contains a PAZ domain and a PIWI domain. It may interact with dicer1 and play a role in short-interfering-RNA-mediated gene silencing. RNA Binding Proteins list , GPCR Collection list , Lipoprotein Antibodies list |
| 4 | Abnova October E-Newsletter - Product News : 908 New Full-length Proteins /137 New Partial-length Proteins. 360 New Monoclonal Antibodies.359 New MaxPab® Antibodies.109 New RNAi Knockdown (Antibody Validated).446 Western Blot (Cell lysate).191 Immunohistochemistry.162 Western Blot (Tissue lysate). 106 RNAi Knockdown (validated). 247 Western Blot (Transfected lysate).50 Sandwich ELISA |
| 5 | Abnova September E-Newsletter - Story and Product Focus |
| 6 | Abnova September E-Newsletter - Product News |
| 7 | Abnova August E-Newsletter - Story and Product Focus |
| 8 | Abnova August E-Newsletter - New Antibody Products and Applications |
| 9 | Abnova July E-Newsletter - Product Banner Highlights |
| 10 | Abnova July E-Newsletter - New Antibody Products and Applications |
| 11 | Abnova June E-Newsletter - Product Banner Highlights |
| 12 | Abnova June E-Newsletter - New Antibody Products and Applications |
Friday, October 21, 2011
Abnova E-Newsletter 2088
Abnova Distributors in Austria
| Abnova Corporation (Germany) - English Service. Abnova GmbH c/o EMBLEM Boxbergring 107 69126 Heidelberg Germany |
Phone : +49-6221-825877 Fax : +49-2381-9994411 Email : sales@abnova.com Website : http://www.abnova.com/ |
|
 |
||
| Eubio. Schwendergasse 17 1150 Wien Austria |
Phone : +43-1-895 01 45 Fax : +43-1-895 01 45 / 14 Email : eubio@eubio.at Website : http://www.eubio.at/ | |
Abnova Distributors in Australia
| Abnova Corporation. 9th Fl., No.108, Jhouzih St., Neihu District, Taipei City, 114 Taiwan |
Phone : +886-2-87511888 Fax : +886-2-87511166 Email : sales@abnova.com Website : http://www.abnova.com/ |
|
|
||
| Life Research. Level 1, 5 Lakeside Drive Burwood East VIC 3151 Australia |
Phone : +61 3 9803 0045 Fax : +61 3 8648 5841 Email : info@liferesearch.com Website : http://liferesearch.com/ Phone : 1300 543 373 (within Australia) |
|
|
||
| Sapphire Bioscience Pty. Ltd. 126 Cope Street Waterloo NSW 2017 Australia |
Phone : +61-2-9698-2022 Fax : +61-2-9698-1022 Email : sales@sapphirebioscience.com Website : http://www.sapphirebioscience.com/ Toll Free : 1800 062 088 | |
Abnova and Clearbridge BioMedics Accelerate Circulating Tumor Cell System into the Research and In Vitro Diagnostic Markets
Abnova and Clearbridge BioMedics Accelerate Circulating Tumor Cell System into the Research and In Vitro Diagnostic Markets
Neihu, Taiwan and Singapore (8 September, 2011)
Clearbridge BioMedics announced today a collaboration, to jointly develop a revolutionary platform that provides a next generation, non-invasive “liquid biopsy” for cancer screening, staging, treatment, and monitoring. Through this collaboration, Abnova will leverage upon Clearbridge BioMedics’ core ClearCell™ CTChip®, which is an advanced microfiltration system for the isolation, enumeration, and retrieval of viable circulating tumor cells (CTCs) from blood. Abnova will then incorporate its proprietary antibody reagents both research-grade antibody reagents and GMP clinical-grade antibodies, to enable the accurate diagnosis of specific medical conditions or diseases.
The new Abnova-Clearbridge BioMedics device provides a powerful adjunctive tool for the traditional yet more technique-demanding and invasive tissue biopsy for cancer staging. Abnova will be responsible for registering and marketing this device globally and is targeting to introduce this new system into the research market in October 2011 and in vitro diagnostic market by 2012.
The metastatic breast, colon and prostate cancers screening and monitoring market is estimated to be more than USD 1 billion. Other screening technologies use more complicated and harsher techniques, as well as general surface biomarkers to capture the tumor cells. These methods irreversibly damage the CTCs and prevent their retrieval in native state. In contrast, Clearbridge BioMedics’ proprietary ClearCell™ System and CTChip® utilizes microfluidics technology and a myriad of crescent-shaped microwells to capture CTCs, with minimal damage. This enables subsequent cell retrieval and staining via monoclonal antibody downstream.
The new Abnova-Clearbridge BioMedics device will facilitate market penetration and greater applications of CTCs. It bridges the gap between clinical research involving the use of a large repertoire of research antibodies for testing and biomarker discovery, and clinical studies that mandate the use of more regulated analyte specific reagents (ASR) antibodies. This new Abnova-Clearbridge BioMedics device, once validated could be deployed in large-scale clinical trials. This will play a key role in helping novel disease-specific biomarkers for new CTC applications to be efficiently developed and commercialized.
“CTCs represent one of three important pillars of system integration for Abnova in the hierarchical organization and interrogation of tissue, cell, and protein,” said Dr. Wilber Huang, President and CEO of Abnova. “Clearbridge BioMedics has elegantly engineered a breakthrough CTC platform, which is unmatched by the competitors, specifically the ability to preserve cell viability after isolation. Up until now, the access to tissue samples is confined to the initial biopsy for diagnosis and staging workup followed by pathological confirmation of resected tissues. The opportunity for non-invasive “liquid biopsy” has tremendous potential in disease management, especially in molecular staging, personalized therapy and recurrence monitoring. Abnova has a plethora of research antibodies and FISH probes to catapult the research market, in addition to a full pipeline of novel IVD biomarkers under development, which are applicable to CTC platform including prostate, ovarian, and lung cancers.
“Our ClearCell™ CTChip® platform empowers researchers, physicians and patients in the rapidly evolving translational research and medical communities,” stated Johnson Chen, Managing Director of Clearbridge BioMedics. “By working with Abnova, we have the opportunity to quickly deploy our breakthrough platform across a wide spectrum of translational research and clinical research settings. With Abnova’s capabilities to efficiently convert monoclonal antibody reagents from a research-grade into an IVD-grade reagent, this new device provides a seamless transition for clinical investigators developing the next generation of biomarkers for early disease diagnosis, prognosis, and companion diagnostic to personalized therapy. Both Abnova and Clearbridge BioMedics will be leveraging each other’s strength and expertise, with a common goal to set a new standard for the CTC industry.”
----------------------------------------------------------------------------------------------------------------------------------------------------------------
About Clearbridge BioMedics
Clearbridge BioMedics specializes in novel platforms with applications in oncology research and diagnostics. It is a National University of Singapore (NUS) spinoff company, that is committed to developing medical devices, which will impact the world and revolutionize cancer diagnostics and patient care, by leveraging on ground-breaking technology from research partners. The ClearCell™ System comprises patent-pending CTChips®, which are able to effectively detect and isolate wholly-intact CTCs (Circulating Tumor Cells) from small quantities of patient blood samples. The isolated CTCs can then be stained directly on the CTChips® for identification and enumeration, or retrieved for further molecular analysis. The ClearCell™ System aims to be the next generation of non-invasive “liquid biopsy” approach for cancer screening, diagnosis, staging, personalised medication, and treatment monitoring. Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America. (www.clearbridgebiomedics.com )
The new Abnova-Clearbridge BioMedics device provides a powerful adjunctive tool for the traditional yet more technique-demanding and invasive tissue biopsy for cancer staging. Abnova will be responsible for registering and marketing this device globally and is targeting to introduce this new system into the research market in October 2011 and in vitro diagnostic market by 2012.
The metastatic breast, colon and prostate cancers screening and monitoring market is estimated to be more than USD 1 billion. Other screening technologies use more complicated and harsher techniques, as well as general surface biomarkers to capture the tumor cells. These methods irreversibly damage the CTCs and prevent their retrieval in native state. In contrast, Clearbridge BioMedics’ proprietary ClearCell™ System and CTChip® utilizes microfluidics technology and a myriad of crescent-shaped microwells to capture CTCs, with minimal damage. This enables subsequent cell retrieval and staining via monoclonal antibody downstream.
The new Abnova-Clearbridge BioMedics device will facilitate market penetration and greater applications of CTCs. It bridges the gap between clinical research involving the use of a large repertoire of research antibodies for testing and biomarker discovery, and clinical studies that mandate the use of more regulated analyte specific reagents (ASR) antibodies. This new Abnova-Clearbridge BioMedics device, once validated could be deployed in large-scale clinical trials. This will play a key role in helping novel disease-specific biomarkers for new CTC applications to be efficiently developed and commercialized.
“CTCs represent one of three important pillars of system integration for Abnova in the hierarchical organization and interrogation of tissue, cell, and protein,” said Dr. Wilber Huang, President and CEO of Abnova. “Clearbridge BioMedics has elegantly engineered a breakthrough CTC platform, which is unmatched by the competitors, specifically the ability to preserve cell viability after isolation. Up until now, the access to tissue samples is confined to the initial biopsy for diagnosis and staging workup followed by pathological confirmation of resected tissues. The opportunity for non-invasive “liquid biopsy” has tremendous potential in disease management, especially in molecular staging, personalized therapy and recurrence monitoring. Abnova has a plethora of research antibodies and FISH probes to catapult the research market, in addition to a full pipeline of novel IVD biomarkers under development, which are applicable to CTC platform including prostate, ovarian, and lung cancers.
“Our ClearCell™ CTChip® platform empowers researchers, physicians and patients in the rapidly evolving translational research and medical communities,” stated Johnson Chen, Managing Director of Clearbridge BioMedics. “By working with Abnova, we have the opportunity to quickly deploy our breakthrough platform across a wide spectrum of translational research and clinical research settings. With Abnova’s capabilities to efficiently convert monoclonal antibody reagents from a research-grade into an IVD-grade reagent, this new device provides a seamless transition for clinical investigators developing the next generation of biomarkers for early disease diagnosis, prognosis, and companion diagnostic to personalized therapy. Both Abnova and Clearbridge BioMedics will be leveraging each other’s strength and expertise, with a common goal to set a new standard for the CTC industry.”
----------------------------------------------------------------------------------------------------------------------------------------------------------------
About Clearbridge BioMedics
Clearbridge BioMedics specializes in novel platforms with applications in oncology research and diagnostics. It is a National University of Singapore (NUS) spinoff company, that is committed to developing medical devices, which will impact the world and revolutionize cancer diagnostics and patient care, by leveraging on ground-breaking technology from research partners. The ClearCell™ System comprises patent-pending CTChips®, which are able to effectively detect and isolate wholly-intact CTCs (Circulating Tumor Cells) from small quantities of patient blood samples. The isolated CTCs can then be stained directly on the CTChips® for identification and enumeration, or retrieved for further molecular analysis. The ClearCell™ System aims to be the next generation of non-invasive “liquid biopsy” approach for cancer screening, diagnosis, staging, personalised medication, and treatment monitoring. Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America. (www.clearbridgebiomedics.com )
About Abnova
Abnova is a biotech company specializing in high throughput monoclonal antibody production. The infrastructure Abnova has developed is a unique combination of world-class technologies and management experience of the IT industry in Taiwan. The company has vastly expanded the scope and availability of bio-tools reagents by taking a genome-wide approach to the production of human recombinant protein and antibody. Abnova has developed a portfolio of integrated and system applications including antibody pairs, ELISA kits, assays, and FISH probes which are essential to the biomarker discovery and translational research institutes. Abnova also has in vitro diagnostic programs focusing on diabetes, infection, and cancer, and fully human antibody therapeutic for the treatment of sepsis. (www.abnova.com )
Precipitor News: Austrian distributor, Anopoli Biomedical, presents Precipitor 16 at Biotechnica
| Precipitor News: Austrian distributor, Anopoli Biomedical, presents Precipitor 16 at Biotechnica |
| 2011/10/11 ~ 2011/10/13 |
| Austrian distributor, Anopoli Biomedical Systems presents Precipitor 16 at Biotechnica in Hannover, Germany Biotechnica (www.biotechnica.de) Date: October 11-13 Place: Hannover, Germany Booth: Anopoli Biomedical Systems Halle 9, Stand E68 Welcome to visit Anopoli Biomedical Systems to find out more about Precipitor 16. See you in Hannover! |
Subscribe to:
Posts (Atom)